Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications. It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Nurix Therapeutics Inc.

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) reported several key trades for Thursday, December 11. The prominent hedge fund manager capit...

HOOD, IBTA, IRDM: Cathie Wood Buys the Dip in Robinhood, Sells Ibotta and Iridium Stocks

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made notable portfolio adjustments on Wednesday, December 10, as revealed in daily fund discl...

Cathie Wood Capitalizes the Surge in Iridium and Biotech Stocks

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Medpace Holdings (MEDP – Research Report) and Nuri...

Analysts Offer Insights on Healthcare Companies: Medpace Holdings (MEDP) and Nurix Therapeutics (NRIX)

An update from Nurix Therapeutics ( ($NRIX) ) is now available. On December 6 and 8, 2025, Nurix Therapeutics announced new clinical data from its ...

Nurix Therapeutics Reports Promising Data at Hematology Meeting

Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Nurix Therapeutics today and set a price target of $33.00. Willey covers the Heal...

Stifel Nicolaus Remains a Buy on Nurix Therapeutics (NRIX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CG Oncology, Inc. (CGON – Research Report), Nurix Th...

Analysts Are Bullish on Top Healthcare Stocks: CG Oncology, Inc. (CGON), Nurix Therapeutics (NRIX)

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Nurix Therapeutics, with a price target of $30.00...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NRIX	$19.07	0.00%	1.89M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NRIX	$19.07	0%	1.89M
3
4
5
6

NRIX

NRIX

No Data Available

Get Nurix Therapeutics Inc. Data in Excel

Get Nurix Therapeutics Inc. Data in Excel